United Therapeutics Corporation
UTHR
Classement en actions
#999
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Prix de l'action
$551.89
Capitalisation boursière
$23.67B
Changement (1 jour)
1.61%
Changement (1 an)
27.55%
Pays
US
Échange United Therapeutics Corporation (UTHR)
Catégorie
Healthcare
Ratio P/E pour United Therapeutics Corporation (UTHR)
Ratio P/E au October 2026 TTM : 17.86
Selon les derniers rapports financiers et le cours de l'action de United Therapeutics Corporation, le ratio P/E actuel (TTM) est de 17.86. À la fin de l’année 2023, le P/E de l’entreprise était de 10.45.
Historique du ratio P/E pour United Therapeutics Corporation de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 17.86 | 33.91% |
| 2024 | 13.34 | 27.71% |
| 2023 | 10.45 | -39.94% |
| 2022 | 17.40 | -14.68% |
| 2021 | 20.39 | 56.46% |
| 2020 | 13.03 | -135.30% |
| 2019 | -36.92 | -559.18% |
| 2018 | 8.04 | -48.39% |
| 2017 | 15.58 | 76.97% |
| 2016 | 8.80 | -20.38% |
| 2015 | 11.06 | -39.73% |
| 2014 | 18.34 | -43.45% |
| 2013 | 32.44 | 254.89% |
| 2012 | 9.14 | -26.27% |
| 2011 | 12.40 | -63.01% |
| 2010 | 33.51 | -76.77% |
| 2009 | 144.23 | -530.83% |
| 2008 | -33.48 | -132.08% |
| 2007 | 104.36 | 517.01% |
| 2006 | 16.91 | -30.30% |
| 2005 | 24.27 | -61.78% |
| 2004 | 63.49 | -230.50% |
| 2003 | -48.65 | 233.78% |
| 2002 | -14.58 | 157.39% |
| 2001 | -5.66 | 50.91% |
| 2000 | -3.75 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | 61.12% |
US
|
|
| -28.36 | -258.75% |
US
|
|
| -24.57 | -237.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 69.78% |
NL
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.